Back to Search
Start Over
Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.
- Source :
-
Blood [Blood] 2015 May 21; Vol. 125 (21), pp. 3360-3. - Publication Year :
- 2015
- Subjects :
- Aged
Antineoplastic Agents therapeutic use
Dasatinib
Humans
In Situ Hybridization, Fluorescence
Male
Reverse Transcriptase Polymerase Chain Reaction
Calreticulin genetics
Fusion Proteins, bcr-abl genetics
Myeloproliferative Disorders drug therapy
Myeloproliferative Disorders genetics
Protein Kinase Inhibitors therapeutic use
Pyrimidines therapeutic use
Thiazoles therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1528-0020
- Volume :
- 125
- Issue :
- 21
- Database :
- MEDLINE
- Journal :
- Blood
- Publication Type :
- Report
- Accession number :
- 25999449
- Full Text :
- https://doi.org/10.1182/blood-2015-03-632893